SEC Tracker
Get the app

Aligos Therapeutics ALGS

Aligos Therapeutics Q1 FY26: revenue $2.8M, up 810%; diluted EPS −$2.21

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Aligos Therapeutics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$2.8M+810% from $311K in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$23.0M−153% from $43.1M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$2.21Against −$2.11 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$30.0M−59% from $73.8M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$23.1MAgainst −$20.9M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aligos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. CEL-SCI CVM public float $19M, Mar 31, 2025, over 18 months old
  2. Relmada Therapeutics RLMD public float $19M, Jun 30, 2025
  3. Fibrogen FGEN public float $21M, Jun 30, 2025
  4. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  5. Imunon IMNN public float $21M, Jun 30, 2025